Junshi Biosciences, Coherus Receive FDA Breakthrough Therapy Status For Toripalimab In Head & Neck Cancer

by Vandana Singh, Benzinga Editor

August 12, 2021 9:10 AM | 1 min read |

The FDA has granted Breakthrough Therapy Designation (BTD) to Shanghai Junshi Biosciences Co Ltd - Coherus BioSciences Inc's CHRS toripalimab for recurrent or metastatic nasopharyngeal carcinoma (NPC).
NPC is a rare tumor of the head and neck.
The designation covers toripalimab combined with chemotherapy (gemcitabine and cisplatin) for the 1st line treatment of NPC.
The FDA had earlier granted BTD for toripalimab monotherapy for patients with recurrent or metastatic NPC with disease progression on or after platinum-containing chemotherapy.
Price Action: CHRS shares are up 7.04% at $14.30 during the premarket session on the last check Thursday.
Related content: Benzinga's Full FDA Calendar.

Posted In: Biotech Long Ideas News Health Care Small Cap FDA Movers Trading Ideas General Briefs FDA Breakthrough Designation neck cancer

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.